Zhang Z, Wu W, Xiahou Z, Song Y
Front Microbiol. 2024; 15:1451160.
PMID: 39318433
PMC: 11420047.
DOI: 10.3389/fmicb.2024.1451160.
Li Y, Heer A, Sloane H, Edelstein D, Tie J, Gibbs P
JAMA Health Forum. 2024; 5(5):e241270.
PMID: 38819797
PMC: 11143467.
DOI: 10.1001/jamahealthforum.2024.1270.
Han Z, Song C, Li D, Zhu W, Sun J, Yao J
J Cancer. 2024; 15(10):3140-3150.
PMID: 38706918
PMC: 11064249.
DOI: 10.7150/jca.94410.
Rong Z, Zheng K, Chen J, Jin X
J Cancer Res Clin Oncol. 2024; 150(3):154.
PMID: 38521878
PMC: 10960765.
DOI: 10.1007/s00432-024-05659-9.
Ye S, Cheng Y, Li P, Zhang L, Zhang L, Huang Y
NPJ Precis Oncol. 2023; 7(1):50.
PMID: 37258779
PMC: 10232411.
DOI: 10.1038/s41698-023-00400-0.
Identification of biomarkers predictive of metastasis development in early-stage colorectal cancer using network-based regularization.
Peixoto C, Lopes M, Martins M, Casimiro S, Sobral D, Grosso A
BMC Bioinformatics. 2023; 24(1):17.
PMID: 36647008
PMC: 9841719.
DOI: 10.1186/s12859-022-05104-z.
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer.
Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H
Mol Cancer. 2022; 21(1):151.
PMID: 35864508
PMC: 9306183.
DOI: 10.1186/s12943-022-01622-9.
Phototherapeutic effect of transformable peptides containing pheophorbide a on colorectal cancer.
Zhang Z, Wang K, Liu M, Hu P, Xu Y, Yin D
Drug Deliv. 2022; 29(1):1608-1619.
PMID: 35612320
PMC: 9135428.
DOI: 10.1080/10717544.2022.2075987.
TRIP13, identified as a hub gene of tumor progression, is the target of microRNA-4693-5p and a potential therapeutic target for colorectal cancer.
Chen Y, Chen D, Qin Y, Qiu C, Zhou Y, Dai M
Cell Death Discov. 2022; 8(1):35.
PMID: 35075117
PMC: 8786872.
DOI: 10.1038/s41420-022-00824-w.
Mucinous Histology Might Be an Indicator for Enhanced Survival Benefit of Chemotherapy in Stage II Colon Cancer.
Huang Y, Ge K, Fu G, Chu J, Wei W
Front Med (Lausanne). 2020; 7:205.
PMID: 32582726
PMC: 7290047.
DOI: 10.3389/fmed.2020.00205.
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.
Koncina E, Haan S, Rauh S, Letellier E
Cancers (Basel). 2020; 12(2).
PMID: 32019056
PMC: 7072488.
DOI: 10.3390/cancers12020319.
Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread.
Kirana C, Peng L, Miller R, Keating J, Glenn C, Shi H
Clin Proteomics. 2019; 16:3.
PMID: 30679934
PMC: 6341757.
DOI: 10.1186/s12014-019-9223-7.
Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients.
Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevska-Angelovska N, Panovski M, Grozdanovska B
Pharmgenomics Pers Med. 2018; 11:193-203.
PMID: 30464574
PMC: 6219100.
DOI: 10.2147/PGPM.S172467.
Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer.
Shelton R, Brotzman L, Crookes D, Robles P, Neugut A
Patient Educ Couns. 2018; 102(2):284-290.
PMID: 30262401
PMC: 6377327.
DOI: 10.1016/j.pec.2018.09.015.
Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production.
Ullmann P, Qureshi-Baig K, Rodriguez F, Ginolhac A, Nonnenmacher Y, Ternes D
Oncotarget. 2016; 7(40):65454-65470.
PMID: 27589845
PMC: 5323168.
DOI: 10.18632/oncotarget.11772.
CD93 gene polymorphism is associated with disseminated colorectal cancer.
Olsen R, Lindh M, Vorkapic E, Andersson R, Zar N, Lofgren S
Int J Colorectal Dis. 2015; 30(7):883-90.
PMID: 26008729
PMC: 4471320.
DOI: 10.1007/s00384-015-2247-1.
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.
Letellier E, Schmitz M, Baig K, Beaume N, Schwartz C, Frasquilho S
Br J Cancer. 2014; 111(4):726-35.
PMID: 25025962
PMC: 4134506.
DOI: 10.1038/bjc.2014.377.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne P, McArt D, Blayney J, Kalimutho M, Greer S, Wang T
Clin Cancer Res. 2013; 20(1):164-75.
PMID: 24170546
PMC: 3885388.
DOI: 10.1158/1078-0432.CCR-13-1354.
Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome.
Hansen A, Freeman T, Arnold S, Starchenko A, Jones-Paris C, Gilger M
Cancer Res. 2013; 73(10):2955-64.
PMID: 23539446
PMC: 3660148.
DOI: 10.1158/0008-5472.CAN-12-2052.
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Stevenson L, Allen W, Turkington R, Jithesh P, Proutski I, Stewart G
Clin Cancer Res. 2012; 18(19):5412-26.
PMID: 22859720
PMC: 3463501.
DOI: 10.1158/1078-0432.CCR-12-1780.
